;PMID: 11470492
;source_file_864.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..147] = [t:45..147]
;2)section:[e:151..192] = [t:151..192]
;3)section:[e:196..344] = [t:196..344]
;4)sentence:[e:348..497] = [t:348..497]
;5)sentence:[e:498..836] = [t:498..836]
;6)sentence:[e:837..1159] = [t:837..1159]
;7)sentence:[e:1160..1302] = [t:1160..1302]
;8)sentence:[e:1303..1523] = [t:1303..1523]
;9)sentence:[e:1524..1652] = [t:1524..1652]
;10)sentence:[e:1653..1804] = [t:1653..1804]
;11)sentence:[e:1806..1909] = [t:1806..1909]
;12)sentence:[e:1910..2034] = [t:1910..2034]
;13)section:[e:2038..2083] = [t:2038..2083]

;section 0 Span:0..39
;Mutat Res. 2001 Aug 8;479(1-2):197-206.
(SEC
  (FRAG (NNP:[0..5] Mutat) (NNP:[6..9] Res) (.:[9..10] .) (CD:[11..15] 2001)
        (CC:[16..19] Aug) (CD:[20..27] 8;479-LRB-1) (HYPH:[27..28] -)
        (CD:[28..29] 2) (-RRB-:[29..30] -RRB-) (CD:[30..34] :197)
        (HYPH:[34..35] -) (CD:[35..38] 206) (.:[38..39] .)))

;sentence 1 Span:45..147
;Inhibition by green tea catechins of metabolic activation of procarcinogens
;by  human cytochrome P450.
;[59..68]:substance:"green tea"
;[69..78]:substance:"catechins"
;[106..120]:substance:"procarcinogens"
;[131..146]:cyp450:"cytochrome P450"
(SENT
  (NP-HLN
    (NP (NN:[45..55] Inhibition))
    (PP (IN:[56..58] by)
      (NP
        (NML (JJ:[59..64] green) (NN:[65..68] tea))
        (NNS:[69..78] catechins)))
    (PP (IN:[79..81] of)
      (NP
        (NP (JJ:[82..91] metabolic) (NN:[92..102] activation))
        (PP (IN:[103..105] of)
          (NP (NNS:[106..120] procarcinogens)))
        (PP (IN:[121..123] by)
          (NP (JJ:[125..130] human)
             (NN:[131..141] cytochrome) (NN:[142..146] P450)))))
    (.:[146..147] .)))

;section 2 Span:151..192
;Muto S, Fujita K, Yamazaki Y, Kamataki T.
(SEC
  (FRAG (NNP:[151..155] Muto) (NNP:[156..158] S,) (NNP:[159..165] Fujita)
        (NNP:[166..167] K) (,:[167..168] ,) (NNP:[169..177] Yamazaki)
        (NNP:[178..179] Y) (,:[179..180] ,) (NNP:[181..189] Kamataki)
        (NNP:[190..192] T.)))

;section 3 Span:196..344
;Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, 
;Hokkaido University, N12W6, Kita-ku, 060-0812, Hokkaido, Sapporo, Japan.
(SEC
  (FRAG (NNP:[196..206] Laboratory) (IN:[207..209] of) (NNP:[210..214] Drug)
        (NNP:[215..225] Metabolism) (POS:[225..226] ,) (NNP:[227..235] Graduate)
        (NNP:[236..242] School) (IN:[243..245] of)
        (NNP:[246..260] Pharmaceutical) (NNPS:[261..269] Sciences)
        (,:[269..270] ,) (NNP:[272..280] Hokkaido) (NNP:[281..291] University)
        (,:[291..292] ,) (NNP:[293..298] N12W6) (,:[298..299] ,)
        (NNP:[300..304] Kita) (HYPH:[304..305] -) (JJ:[305..307] ku)
        (,:[307..308] ,) (CD:[309..312] 060) (HYPH:[312..317] -0812)
        (JJ:[317..318] ,) (NNP:[319..327] Hokkaido) (,:[327..328] ,)
        (NNP:[329..336] Sapporo) (,:[336..337] ,) (NNP:[338..343] Japan)
        (.:[343..344] .)))

;sentence 4 Span:348..497
;Catechins, major polyphenol constituents of green tea, are potent 
;chemopreventive agents against cancers caused by chemical carcinogens in 
;rodents.
;[348..357]:substance:"Catechins"
;[365..375]:substance:"polyphenol"
;[392..401]:substance:"green tea"
;[415..437]:substance:"chemopreventive agents"
;[473..484]:substance:"carcinogens"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[348..357] Catechins) (,:[357..358] ,))
      (NP
        (NP (JJ:[359..364] major) (NN:[365..375] polyphenol)
            (NNS:[376..388] constituents))
        (PP (IN:[389..391] of)
          (NP (JJ:[392..397] green) (NN:[398..401] tea)))))
    (,:[401..402] ,)
    (VP (VBP:[403..406] are)
      (NP-PRD
        (NP (JJ:[407..413] potent)
           (JJ:[415..430] chemopreventive) (NNS:[431..437] agents))
        (PP (IN:[438..445] against)
          (NP
            (NP (NNS:[446..453] cancers))
            (VP (VBN:[454..460] caused)
              (NP (-NONE-:[460..460] *))
              (PP (IN:[461..463] by)
                (NP-LGS (JJ:[464..472] chemical) (NNS:[473..484] carcinogens)))
              (PP-LOC (IN:[485..487] in)
                (NP (NNS:[489..496] rodents))))))))
    (.:[496..497] .)))

;sentence 5 Span:498..836
;The effects of four epicatechin derivatives, epigallocatechin gallate 
;(EGCG), epicatechin gallate (ECG), epigallocatechin (EGC) and epicatechin
;(EC),  on the metabolic activation of benzo[a]pyrene (B[a]P), 
;2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) and aflatoxin B(1) 
;(AFB(1)) by human cytochrome P450 (CYP) were examined.
;[518..541]:substance:"epicatechin derivatives"
;[543..567]:substance:"epigallocatechin gallate"
;[570..574]:substance:"EGCG"
;[577..596]:substance:"epicatechin gallate"
;[598..601]:substance:"ECG"
;[604..620]:substance:"epigallocatechin"
;[622..625]:substance:"EGC"
;[631..642]:substance:"epicatechin"
;[644..646]:substance:"EC"
;[681..695]:substance:"benzo[a]pyrene"
;[697..702]:substance:"B[a]P"
;[706..754]:substance:"2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine"
;[756..760]:substance:"PhIP"
;[766..780]:substance:"aflatoxin B(1)"
;[783..789]:substance:"AFB(1)"
;[800..815]:cyp450:"cytochrome P450"
;[817..820]:cyp450:"CYP"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[498..501] The) (NNS:[502..509] effects))
      (PP (IN:[510..512] of)
        (NP
          (NP (CD:[513..517] four)
             (NN:[518..529] epicatechin) (NNS:[530..541] derivatives))
          (,:[541..542] ,)
          (NP
            (NP
              (NP (NN:[543..559] epigallocatechin) (NN:[560..567] gallate))
              (NP (-LRB-:[569..570] -LRB-) (NN:[570..574] EGCG)
                  (-RRB-:[574..575] -RRB-)))
            (,:[575..576] ,)
            (NP
              (NP (NN:[577..588] epicatechin) (NN:[589..596] gallate))
              (NP (-LRB-:[597..598] -LRB-) (NN:[598..601] ECG)
                  (-RRB-:[601..602] -RRB-)))
            (,:[602..603] ,)
            (NP
              (NP (NN:[604..620] epigallocatechin))
              (NP (-LRB-:[621..622] -LRB-) (NN:[622..625] EGC)
                  (-RRB-:[625..626] -RRB-)))
            (CC:[627..630] and)
            (NP
              (NP (NN:[631..642] epicatechin))
              (NP (-LRB-:[643..644] -LRB-) (NN:[644..646] EC)
                  (-RRB-:[646..647] -RRB-))))))
      (,:[647..648] ,)
      (PP (IN:[650..652] on)
        (NP
          (NP (DT:[653..656] the) (JJ:[657..666] metabolic)
              (NN:[667..677] activation))
          (PP (IN:[678..680] of)
            (NP
              (NP
                (NP (NN:[681..695] benzo-LSB-a-RSB-pyrene))
                (NP (-LRB-:[696..697] -LRB-) (NN:[697..702] B-LSB-a-RSB-P)
                    (-RRB-:[702..703] -RRB-)))
              (,:[703..704] ,)
              (NP
                (NP
                    (NN:[706..754] 2-amino-1-methyl-6-phenylimidazo--LSB-4,5-b-RSB-pyridine))
                (NP (-LRB-:[755..756] -LRB-) (NN:[756..760] PhIP)
                    (-RRB-:[760..761] -RRB-)))
              (CC:[762..765] and)
              (NP
                (NP (NN:[766..775] aflatoxin) (NN:[776..780] B-LRB-1-RRB-))
                (NP (-LRB-:[782..783] -LRB-) (NN:[783..789] AFB-LRB-1-RRB-)
                    (-RRB-:[789..790] -RRB-)))))
          (PP (IN:[791..793] by)
            (NP
              (NP (JJ:[794..799] human)
                 (NN:[800..810] cytochrome) (NN:[811..815] P450))
              (NP (-LRB-:[816..817] -LRB-) (NN:[817..820] CYP)
                  (-RRB-:[820..821] -RRB-)))))))
    (VP (VBD:[822..826] were)
      (VP (VBN:[827..835] examined)
        (NP-1 (-NONE-:[835..835] *))))
    (.:[835..836] .)))

;sentence 6 Span:837..1159
;B[a]P, PhIP and AFB(1)  were activated by respective human CYP1A1, CYP1A2 and
;CYP3A4 expressed in the  membrane fraction of genetically engineered
;Salmonella typhimurium (S.  typhimurium) TA1538 cells harboring the human CYP
;and human NADPH-CYP reductase  (OR), when the membrane fraction was added to
;S. typhimurium TA98.
;[837..842]:substance:"B[a]P"
;[844..848]:substance:"PhIP"
;[853..859]:substance:"AFB(1)"
;[896..902]:cyp450:"CYP1A1"
;[904..910]:cyp450:"CYP1A2"
;[915..921]:cyp450:"CYP3A4"
;[1058..1061]:cyp450:"CYP"
;[1072..1091]:substance:"NADPH-CYP reductase"
;[1094..1096]:substance:"OR"
(SENT
  (S
    (NP-SBJ-2 (NN:[837..842] B-LSB-a-RSB-P) (,:[842..843] ,)
              (NN:[844..848] PhIP) (CC:[849..852] and)
              (NN:[853..859] AFB-LRB-1-RRB-))
    (VP (VBD:[861..865] were)
      (VP (VBN:[866..875] activated)
        (NP-2 (-NONE-:[875..875] *))
        (PP (IN:[876..878] by)
          (NP-LGS
            (NP (JJ:[879..889] respective) (JJ:[890..895] human)
              (NML (NN:[896..902] CYP1A1) (,:[902..903] ,)
                   (NN:[904..910] CYP1A2) (CC:[911..914] and)
                   (NN:[915..921] CYP3A4)))
            (VP (VBN:[922..931] expressed)
              (NP (-NONE-:[931..931] *))
              (PP-LOC (IN:[932..934] in)
                (NP
                  (NP (DT:[935..938] the) (NN:[940..948] membrane)
                      (NN:[949..957] fraction))
                  (PP (IN:[958..960] of)
                    (NML
                      (NML
                        (ADJP (RB:[961..972] genetically)
                              (VBN:[973..983] engineered))
                        (NML
                          (NML
                            (NML (NNP:[984..994] Salmonella)
                                 (NNP:[995..1006] typhimurium))
                            (NML (-LRB-:[1007..1008] -LRB-)
                                 (NNP:[1008..1010] S.)
                                 (NNP:[1012..1023] typhimurium)
                                 (-RRB-:[1023..1024] -RRB-)))
                          (NN:[1025..1031] TA1538))
                        (NNS:[1032..1037] cells))
                      (VP (VBG:[1038..1047] harboring)
                        (NP
                          (NP (DT:[1048..1051] the) (JJ:[1052..1057] human)
                              (NN:[1058..1061] CYP))
                          (CC:[1062..1065] and)
                          (NP (JJ:[1066..1071] human)
                            
                            (NML (NN:[1072..1077] NADPH) (HYPH:[1077..1078] -)
                                 (NN:[1078..1081] CYP))
                            (NN:[1082..1091] reductase)
                            (PRN (-LRB-:[1093..1094] -LRB-) (NN:[1094..1096] OR)
                                 (-RRB-:[1096..1097] -RRB-))))))))))))
        (,:[1097..1098] ,)
        (SBAR-ADV
          (WHADVP-3 (WRB:[1099..1103] when))
          (S
            (NP-SBJ-1 (DT:[1104..1107] the) (NN:[1108..1116] membrane)
                      (NN:[1117..1125] fraction))
            (VP (VBD:[1126..1129] was)
              (VP (VBN:[1130..1135] added)
                (NP-1 (-NONE-:[1135..1135] *))
                (PP-CLR (TO:[1136..1138] to)
                  (NP
                    (NP (NNP:[1139..1141] S.) (NNP:[1142..1153] typhimurium))
                    (NP (NN:[1154..1158] TA98))))
                (ADVP-TMP-3 (-NONE-:[1158..1158] *T*))))))))
    (.:[1158..1159] .)))

;sentence 7 Span:1160..1302
;Galloylated  catechins, ECG and EGCG inhibited the mutagenic activation
;potently, while EGC  and EC showed relatively weak inhibitory effects.
;[1173..1182]:substance:"catechins"
;[1184..1187]:substance:"ECG"
;[1192..1196]:substance:"EGCG"
;[1248..1251]:substance:"EGC"
;[1257..1259]:substance:"EC"
(SENT
  (S
    (NP-SBJ
      (NP (VBN:[1160..1171] Galloylated) (NNS:[1173..1182] catechins)
          (,:[1182..1183] ,))
      (NP (NN:[1184..1187] ECG) (CC:[1188..1191] and) (NN:[1192..1196] EGCG)))
    (VP (VBD:[1197..1206] inhibited)
      (NP (DT:[1207..1210] the) (JJ:[1211..1220] mutagenic)
          (NN:[1221..1231] activation))
      (ADVP (RB:[1232..1240] potently))
      (,:[1240..1241] ,)
      (SBAR-ADV (IN:[1242..1247] while)
        (S
          (NP-SBJ (NN:[1248..1251] EGC) (CC:[1253..1256] and)
                  (NN:[1257..1259] EC))
          (VP (VBD:[1260..1266] showed)
            (NP
              (ADJP (RB:[1267..1277] relatively) (JJ:[1278..1282] weak))
              (JJ:[1283..1293] inhibitory) (NNS:[1294..1301] effects))))))
    (.:[1301..1302] .)))

;sentence 8 Span:1303..1523
;Catechins also inhibited the  oxidations of typical substrates catalyzed by
;human CYPs, namely ethoxycoumarin  O-deethylation by CYP1A1, ethoxyresorufin
;O-deethylation by CYP1A2 and midazolam  1'-hydroxylation by CYP3A4.
;[1303..1312]:substance:"Catechins"
;[1355..1365]:substance:"substrates"
;[1385..1389]:cyp450:"CYPs"
;[1398..1412]:substance:"ethoxycoumarin"
;[1432..1438]:cyp450:"CYP1A1"
;[1440..1455]:substance:"ethoxyresorufin"
;[1474..1480]:cyp450:"CYP1A2"
;[1485..1494]:substance:"midazolam"
;[1516..1522]:cyp450:"CYP3A4"
(SENT
  (S
    (NP-SBJ (NNS:[1303..1312] Catechins))
    (VP
      (ADVP (RB:[1313..1317] also))
      (VBD:[1318..1327] inhibited)
      (NP
        (NP (DT:[1328..1331] the) (NNS:[1333..1343] oxidations))
        (PP (IN:[1344..1346] of)
          (NP
            (NP (JJ:[1347..1354] typical) (NNS:[1355..1365] substrates))
            (VP (VBN:[1366..1375] catalyzed)
              (NP (-NONE-:[1375..1375] *))
              (PP (IN:[1376..1378] by)
                (NP-LGS
                  (NP (JJ:[1379..1384] human) (NNS:[1385..1389] CYPs))
                  (,:[1389..1390] ,)
                  (NP
                    (ADVP (RB:[1391..1397] namely))
                    (NP
                      (NP (NN:[1398..1412] ethoxycoumarin)
                          (NN:[1414..1428] O-deethylation))
                      (PP (IN:[1429..1431] by)
                        (NP (NN:[1432..1438] CYP1A1))))
                    (,:[1438..1439] ,)
                    (NP
                      (NP (NN:[1440..1455] ethoxyresorufin)
                          (NN:[1456..1470] O-deethylation))
                      (PP (IN:[1471..1473] by)
                        (NP (NN:[1474..1480] CYP1A2))))
                    (CC:[1481..1484] and)
                    (NP
                      (NP (NN:[1485..1494] midazolam)
                          (NN:[1496..1512] 1'-hydroxylation))
                      (PP (IN:[1513..1515] by)
                        (NP (NN:[1516..1522] CYP3A4))))))))))))
    (.:[1522..1523] .)))

;sentence 9 Span:1524..1652
;The IC(50) values of catechins for the inhibition of  human CYP were roughly
;the same as those seen in the mutagenic activation.
;[1528..1534]:quantitative-name:"IC(50)"
;[1545..1554]:substance:"catechins"
;[1584..1587]:cyp450:"CYP"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1524..1527] The) (NN:[1528..1534] IC-LRB-50-RRB-)
          (NNS:[1535..1541] values))
      (PP (IN:[1542..1544] of)
        (NP (NNS:[1545..1554] catechins)))
      (PP (IN:[1555..1558] for)
        (NP
          (NP (DT:[1559..1562] the) (NN:[1563..1573] inhibition))
          (PP (IN:[1574..1576] of)
            (NP (JJ:[1578..1583] human) (NN:[1584..1587] CYP))))))
    (VP (VBD:[1588..1592] were)
      (ADJP-PRD
        (ADJP (RB:[1593..1600] roughly) (DT:[1601..1604] the)
              (JJ:[1605..1609] same))
        (PP (IN:[1610..1612] as)
          (NP
            (NP (DT:[1613..1618] those))
            (VP (VBN:[1619..1623] seen)
              (NP (-NONE-:[1623..1623] *))
              (PP-LOC (IN:[1624..1626] in)
                (NP (DT:[1627..1630] the) (JJ:[1631..1640] mutagenic)
                    (NN:[1641..1651] activation))))))))
    (.:[1651..1652] .)))

;sentence 10 Span:1653..1804
;EGCG  inhibited other forms of human CYP such as CYP2A6, CYP2C19 and CYP2E1, 
;indicating the non-specific inhibitory effects of EGCG toward human CYPs.
;[1653..1657]:substance:"EGCG"
;[1690..1693]:cyp450:"CYP"
;[1702..1708]:cyp450:"CYP2A6"
;[1710..1717]:cyp450:"CYP2C19"
;[1722..1728]:cyp450:"CYP2E1"
;[1781..1785]:substance:"EGCG"
;[1799..1803]:cyp450:"CYPs"
(SENT
  (S
    (NP-SBJ (NN:[1653..1657] EGCG))
    (VP (VBD:[1659..1668] inhibited)
      (NP
        (NP (JJ:[1669..1674] other) (NNS:[1675..1680] forms))
        (PP (IN:[1681..1683] of)
          (NP (JJ:[1684..1689] human) (NN:[1690..1693] CYP)))
        (PP (JJ:[1694..1698] such) (IN:[1699..1701] as)
          (NP (NN:[1702..1708] CYP2A6) (,:[1708..1709] ,)
              (NN:[1710..1717] CYP2C19) (CC:[1718..1721] and)
              (NN:[1722..1728] CYP2E1))))
      (,:[1728..1729] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1729..1729] *))
        (VP (VBG:[1731..1741] indicating)
          (NP
            (NP (DT:[1742..1745] the)
              (ADJP (AFX:[1746..1749] non) (HYPH:[1749..1750] -)
                    (JJ:[1750..1758] specific))
              (JJ:[1759..1769] inhibitory) (NNS:[1770..1777] effects))
            (PP (IN:[1778..1780] of)
              (NP (NN:[1781..1785] EGCG)))
            (PP (IN:[1786..1792] toward)
              (NP (JJ:[1793..1798] human) (NNS:[1799..1803] CYPs)))))))
    (.:[1803..1804] .)))

;sentence 11 Span:1806..1909
;Furthermore, EGCG inhibited human NADPH-cytochrome CYP reductase (OR) with a 
;K(i) value of 2.5 microM.
;[1819..1823]:substance:"EGCG"
;[1840..1870]:substance:"NADPH-cytochrome CYP reductase"
;[1872..1874]:substance:"OR"
;[1884..1888]:quantitative-name:"K(i)"
;[1898..1901]:quantitative-value:"2.5"
;[1902..1908]:quantitative-units:"microM"
(SENT
  (S
    (ADVP (RB:[1806..1817] Furthermore))
    (,:[1817..1818] ,)
    (NP-SBJ (NN:[1819..1823] EGCG))
    (VP (VBD:[1824..1833] inhibited)
      (NP
        (NP (JJ:[1834..1839] human)
          
          (NML (NN:[1840..1845] NADPH) (HYPH:[1845..1846] -)
               (NN:[1846..1856] cytochrome) (NN:[1857..1860] CYP))
          (NN:[1861..1870] reductase))
        (PRN (-LRB-:[1871..1872] -LRB-)
          (NP (NN:[1872..1874] OR))
          (-RRB-:[1874..1875] -RRB-)))
      (PP (IN:[1876..1880] with)
        (NP
          (NP (DT:[1881..1882] a) (NN:[1884..1888] K-LRB-i-RRB-)
              (NN:[1889..1894] value))
          (PP (IN:[1895..1897] of)
            (NP (CD:[1898..1901] 2.5) (NN:[1902..1908] microM))))))
    (.:[1908..1909] .)))

;sentence 12 Span:1910..2034
;These results suggest that the inhibition of the  enzyme activity of CYP is
;accounted for partially by the inhibition of OR.
;[1960..1966]:substance:"enzyme"
;[1979..1982]:cyp450:"CYP"
;[2031..2033]:substance:"OR"
(SENT
  (S
    (NP-SBJ (DT:[1910..1915] These) (NNS:[1916..1923] results))
    (VP (VBP:[1924..1931] suggest)
      (SBAR (IN:[1932..1936] that)
        (S
          (NP-SBJ-1
            (NP (DT:[1937..1940] the) (NN:[1941..1951] inhibition))
            (PP (IN:[1952..1954] of)
              (NP
                (NP (DT:[1955..1958] the) (NN:[1960..1966] enzyme)
                    (NN:[1967..1975] activity))
                (PP (IN:[1976..1978] of)
                  (NP (NN:[1979..1982] CYP))))))
          (VP (VBZ:[1983..1985] is)
            (VP (VBN:[1986..1995] accounted)
              (NP-1 (-NONE-:[1995..1995] *))
              (PRT (IN:[1996..1999] for))
              (PP
                (ADVP (RB:[2000..2009] partially))
                (IN:[2010..2012] by)
                (NP
                  (NP (DT:[2013..2016] the) (NN:[2017..2027] inhibition))
                  (PP (IN:[2028..2030] of)
                    (NP (NN:[2031..2033] OR))))))))))
    (.:[2033..2034] .)))

;section 13 Span:2038..2083
;PMID: 11470492 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2038..2042] PMID) (::[2042..2043] :) (CD:[2044..2052] 11470492)
        (IN:[2053..2054] -LSB-) (NNP:[2054..2060] PubMed) (HYPH:[2061..2062] -)
        (JJ:[2063..2070] indexed) (IN:[2071..2074] for)
        (NNP:[2075..2083] MEDLINE-RSB-)))
